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EDITORIAL 
 
The use of enrichment to reduce statistically indeterminate or 
negative trials in critical care 
Randomised controlled trials (RCTs) are clinical experiments that assess whether the intervention 
tested improves the primary outcome. Random allocation of subjects and assessment of their 
outcomes in experiments to infer causality is credited to Ronald Fisher and Jerzy Neyman [1]. The 
underpinning theory of RCTs is that the difference in primary outcome between the treated and the 
controls provides an unbiased estimate of the causal effect of the intervention on the outcome. All 
RCTs start with a study population derived by inclusion and exclusion criteria. There is equipoise 
about the treatment effect. Randomisation ensures that measurable and, more importantly, 
unmeasurable characteristics are distributed in a way that reduces confounding to chance.  The 
allocation of the next subject is not predictable. The subjects and investigators are unware of the 
allocation, which minimises bias. Compliance with the trial protocol is assessed and reported. The a-
priori-designed analyses plans are adhered to when reporting. Thus, well-designed and conducted 
RCTs potentially provide the best graded evidence base for clinical care [2]. 
Most RCTs randomly allocate individuals and test whether the intervention is superior to 
standard of care, although we could also test for equivalence and non-inferiority of the new treatment 
[3]. Positive result from a well conducted RCT is accepted and incorporated into clinical practice, 
especially when replicated in two or more trials. When it is a statistically indeterminate or negative 
RCT and the intervention tested has biological plausibility, it makes us consider whether there are 
patient subsets who might have benefited and could we characterise them to inform future trial 
design? One reason for considering this argument is that critical care (ICU) trials are most often 
conducted in acute respiratory distress syndrome (ARDS [4]) and sepsis [5,6] and enroll 
heterogeneous populations. In this editorial, we highlight ‘The only formula of physiological statistics’ 
[7] proposed by David Sackett as a way of reasoning statistically negative RCTs (Fig. 1). For 
understanding risk domains in RCT participants, the readers are directed to in depth review by 
Feudtner and colleagues [8]. The focus of our paper is to briefly discuss how signal enrichment and 
noise reduction could help reduce statistically negative RCTs.  We use examples from ARDS and 
sepsis literature, as they have major overlaps in their biology [9,10] and the most common aetiology 
of ARDS is sepsis [11].  
 
Heterogeneity 
Heterogeneity is the norm in sepsis and ARDS patients. Heterogeneity is the inter-individual variation 
in susceptibility to illness or outcome from illness that arises from factors that do not clearly delineate 
a high risk sub-population. Individuals vary in their susceptibility to both the illness itself and the 
outcomes from the illness. Birth cohort studies have highlighted that the variation in risk of outcomes 
and susceptibility to illness is determined very early on in life [12]. Although genetic and 
environmental factors are important contributors, heterogeneity is often a random event [13]. The 
heterogeneity of sepsis and ARDS populations in their risk factors for critical illness, age, 
comorbidities, number and severity of organ failures is well established [14,15].  Although less well 
established, this is presumably true for the underlying mechanisms of these syndromes [9,10,16].  
Susceptibility to any specific therapy is likely to be driven by the biology of an individual patient’s 
sepsis or ARDS as well as their underlying risk of death. There are a number of scenarios that may 
generate different treatment responses: 
 
 
Grouping based on susceptibility to tested treatment  
It seems intuitive that patients enrolled in a clinical trial should have a mechanism that can be 
responsive to that intervention.  Trials of inotropes in septic shock should target patients with 
decreased cardiac output [17], trials of PEEP in ARDS should enrol patients who have recruitable 
lung [18], and trials targeted at endotoxin removal should be endotoxinaemic [19].  Despite this, 
critical care trials, either for reasons of pragmatic design, lack of a biomarker, or lack of agreement on 
the mechanism of the treatment are often not designed with this in mind.  However, recent advances 
suggest several novel strategies.    
Enrichment can be achieved by using stratification on a biomarker that is linked to the tested 
treatment. Meisel and colleagues proposed a sepsis subgroup with low monocyte HLA-DR expression 
as a marker of immunosuppression who had an enhanced response to granulocyte–macrophage 
colony-stimulating factor (GM-CSF) in an early phase trial [20]. In ICU patients, cytomegalovirus 
(CMV) reactivation is associated with adverse outcomes [21]. Therefore, CMV-seropositive status in 
ICU patients could stratify patients for administering prophylaxis to prevent CMV reactivation and 
improve outcomes [22].  
Enrichment can also be achieved by using transient response to an intervention that is going 
to be tested in the trial. Goligher and colleagues re-analysed data from two ARDS trials to test the 
hypothesis that improvement in oxygenation in response to positive end expiratory pressure (PEEP) 
will identify a treatment-responsive ARDS subgroup. The authors highlight that a lower risk of death in 
the PEEP-responsive group will benefit from a RCT reassessing the value of higher versus lower 
PEEP in ARDS [23].  This approach is particularly appealing in trials of physiologic interventions with 
an immediately measurable physiologic response, and relies on the assumption, which needs to be 
validated, that physiologic response will translate in to outcome benefit.  The design issue here is that 
physiologic response is used as an enrolment criterion not an outcome. 
In many cases, the mechanistic endotypes of critical illness syndromes are less clear. In 
these situations, investigators have relied on empiric clustering algorithms to group patients based on 
clinical and biologic variables.  There are numerous methods such as latent class analyses and 
clustering algorithms, depending on the data available to identify these groups [24, 25].    
Sometimes, subgroups identified with these techniques suggest underlying biologic 
responses to illness. For example, Davenport et al. used whole blood leukocyte gene expression in 
sepsis due to community acquired pneumonia, and observed two patient clusters based on empiric 
algorithms (sepsis response signatures or SRS). A patient cluster identified as SRS1 had an 
immunosuppressed phenotype and greater mortality, which could identify a biological response group 
for immune reconstitution therapies in future RCTs [26].  Recently, Calfee et al. re-analysed data from 
three ARDS RCTs [27,28] by including additional biomarkers of inflammation, alveolar and endothelial 
injury and tested whether subgroups of patients identified with latent class analysis could be identified 
within ARDS RCT populations.  In all three RCTs, they consistently identified two subgroups of 
ARDS, with one subgroup showing greater inflammation amongst other biomarker characteristics and 
mortality. This ARDS subgroup also had a statistically significant interaction with the treatments tested 
in the RCTs – mechanical ventilation and fluid management. The implication of statistical interaction 
with the treatment is that it potentially identifies a subgroup of patients who on average are likely to 
have different treatment response to the intervention tested. The principal challenges from these two 
studies for future trial design includes the retrospective lookback analyses, measurement of selected 
biomarkers and use of latent class analyses that removes data granularity by using standard normal 
distribution. Thus, the questions remain as to whether we could prospectively identify similar patient 
groups for a trial inclusion and could we do this using a limited set of clinically feasible markers [27-
29].   
Wong et al. identified two septic shock subsets in paediatric population using gene 
expression data. The authors then tested whether these septic shock subgroups differed in the 
association to treatment effect of corticosteroids. They highlighted two main phenotypes differentiated 
by inflammation and a four-fold difference in mortality by steroid treatment category. They proposed 
that this gene expression profile could enrich septic shock population for future RCTs [30,31]. 
This concept of corticosteroid responsiveness has also been investigated in adult septic 
shock population by Bentzer et al. Corticosteroid responsiveness was defined as improved odds of 
survival. Importantly, they used plasma cytokine levels and had propensity score-matched septic 
shock patients who didn't receive corticosteroids as controls. Corticosteroid responsiveness was 
identified by detection of interleukin-3 (IL3), IL6, or chemokine ligand-4 above predefined threshold 
values [32]. The additional value of this study was that plasma cytokine measurement could be done 
as a point-of-care test. 
 
Grouping based on difference in susceptibility to death 
The differences in the effect of treatments across the range of severity of illness is well described [33]. 
This is true because the effect of treatment is relative to the baseline risk of death, and therefore the 
attributable benefit of treatment declines as baseline risk declines [34].  The difference in outcome 
over the changing baseline risk is called the heterogeneity in treatment effect. These findings are 
more problematic as the risks of therapy are often fixed and not related to underlying risk of death. 
Extending this argument, if a trial population has different representations of low and very high risk 
populations, the treatment effect is likely to vary significantly.  Iwashyna et al. recently demonstrated 
this mathematical phenomenon using simulations of RCTs in sepsis and in ARDS. They showed that 
as the risk of death changes from low to high, the difference in mortality between the intervention and 
the control arm increases, thereby highlighting a sub-group that is likely to benefit from the 
intervention [35].   
This model may itself be overly simplistic. Let us consider the relationship between sepsis 
and mortality. The term-attributable risk of sepsis refers to the difference in probability of death 
between patients with sepsis and those without sepsis. In the context of a RCT, the attributable 
benefit of an intervention refers to improvement in mortality in the treated compared with controls. 
Mathematically, the attributable benefit of a therapy must vary with the baseline risk of death. 
Therefore, enrolling patients at higher risk of death or other outcomes will reduce the study sample 
size requirements, which is prognostic enrichment.  
However, there may be more interesting phenomena occurring here. First, the baseline risk of 
death in a sepsis RCT population is related to illness severity, which is often measured using 
APACHE-2 and organ dysfunction scores. Our assumption in a RCT is that illness severity is caused 
by sepsis and therefore should get better with the treatment tested. One could argue that these 
severity scores may well be markers for unrelated biologic phenomenon. This has been reported in 
sepsis. If we account for pre-illness deterioration, very different sepsis-outcome relationships emerge 
[36]. Therefore, an argument would be, treatment-effect heterogeneity may be a simple way of clinical 
trial enrichment for poorly understood mechanistic phenomena.  Second, for a given illness, the 
outcome of interest has more than one causal mechanism or many risk factors [37]. A patient with 
more attributable risk from sepsis is likely to have greater attributable benefit from treatment. An 
extreme example would be: two patients with similar illness severity score but one is a healthy 20 
year-old with sepsis and the other is a 70 year-old with pneumonia and severe comorbidity. 
There are two ways to take advantage of this phenomenon. First, in the design phase of the 
trial, enrolment can be restricted to the more severe end of the spectrum. A good example to consider 
in this context is the recombinant activated Protein C (drotrecogin alfa (activated) (DrotAA) trials in 
sepsis. The first phase-3 trial was stopped early for efficacy as crude mortality in the intention-to-treat 
population was reduced by 6.1% with a relative risk reduction of 19.4% [38]. However, sub-group 
analyses implied that this unexpected efficacy was due to differences in treatment response in a high 
risk of death sub-population. This lead to two further trials, one in low risk of death population [39] and 
a second trial in a high risk of death population enriched by persistent vasopressor requirement after 
resuscitation [40]. Both trials were statistically negative. The first [39] highlights the important concept 
that as the risk of death due to underlying illness and the benefit of therapy declines, the risk of 
therapy predominates, as highlighted by increased risk of bleeding.  Thus, it is not always effective as 
an enrolment strategy to focus of high risk of outcome event population, especially when the outcome 
is determined by non-modifiable risk factors such as age or comorbidities.  
Second, in the analysis phase of trials, we can delineate sub-groups based on treatment 
effect with mathematical approaches to incorporating baseline risk with limited covariates such as a 
logistic regression model or the more recently described Virtual Twins method [41]. 
 
 
In summary, trial enrichment is not always efficient, as it represents a trade-off between the 
underpinning research time it takes to identify how best to perform enrichment, the patients lost during 
the process of enrichment as they do not meet the criteria, and the magnitude of increase in signal 
that is derived.  Our discussions thus far have deliberately avoided the terms ‘personalised’ and 
‘precision’ medicine. When using enrichment approaches as described above, we are increasing the 
pre-test probability and likelihood of treatment response at a cohort level, not at an individual level. 
Our paper highlights the need to have a deeper biological and granular understanding of these two 
critical illnesses to perform enrichment. In any RCT, there will be patients who survive irrespective of 
treatment allocation either due to: low-risk of death; placebo response; spontaneous improvement; or 
survival ‘due’ to the intervention (true responders). Similarly, in any RCT there will be patients who will 
die irrespective of the intervention. The likelihood of a positive trial could be improved by enriching 
true responders based on their susceptibility to either the tested treatment or to death or ideally a 
combination of the two approaches.  
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Figure 1 ‘The only formula of physiological statistics’ [7] 
 𝑪𝒐𝒏𝒇𝒊𝒅𝒆𝒏𝒄𝒆	𝒊𝒏	𝒕𝒓𝒊𝒂𝒍	𝒓𝒆𝒔𝒖𝒍𝒕 = 	𝑺𝒊𝒈𝒏𝒂𝒍𝑵𝒐𝒊𝒔𝒆 	𝑿	 𝑺𝒂𝒎𝒑𝒍𝒆𝒔𝒊𝒛𝒆 
 
Let us consider a drug trial with mortality as the primary outcome for explaining this formula. The 
confidence in the trial result includes the mortality difference between the intervention and the control 
arm and the measure of precision around that difference, i.e. confidence interval (CI). The signal 
refers to the ‘magnitude’ of difference in mortality between the intervention and control arm, higher 
difference increases our confidence in the trial result, especially when it is replicated in many RCTs. 
The noise refers to all numeric and descriptive sources of variations (heterogeneity) in a trial and 
includes inter-individual variation in responses to treatment. Therefore, to get positive RCTs with 
confidence in their result, aside from increasing sample size, our options are to either increase the 
signal and/or reduce the noise. The easy explanation of a negative RCT is that intervention does not 
work. However, if the intervention tested has biological plausibility, then understanding how to 
optimise the signal is important. Superiority RCTs aim to demonstrate that the intervention improves 
outcome compared with standard care (i.e. intervention is better than standard care). Equivalence 
RCTs aim to demonstrate that the new intervention is as good as the old intervention, within a pre-
specified range. Non-inferiority RCTs aim to demonstrate that although the new intervention is inferior 
to the old intervention in improving outcomes, the difference is not clinically significant. In all these 
RCTS, the conclusion about the effect of the intervention on primary outcome represents the average 
effect across the included population. It does not give any clue whether the patient in front of you will 
benefit or not. We also don't have any idea about the magnitude of benefit or harm for an individual 
patient that you are going to use this drug on. 
RCT, randomised clinical trial 
 
